Mankind Pharma: Fundamental Analysis | Stocks in Focus - Part 3 | CA Rachana Ranade
Published: 2025-01-22
Status:
Available
|
Analyzed
Published: 2025-01-22
Status:
Available
|
Analyzed
Predictions from this Video
Incorrect: 0
Prediction
Topic
Status
Mankind Pharma experienced revenue growth of 11% in FY23 and 13% in FY24.
"from 22 to 23 the revenue grow at 11 from 23 to 24 the revenue grow at 13"
Pending
Mankind Pharma's Q2 FY25 revenue increased by 11% compared to Q2 FY24.
"Now even if I were to talk about the q2 numbers, q2 fy2 has increased by 11 in comparison with q2 fy2."
Pending
Mankind Pharma has maintained its number one position for seven years with a 15.4% share of prescriptions.
"they are maintaining their rank one over the last seven years with a prescription share of 15.4."
Pending
Mankind Pharma's market share in the chronic disease segment has grown from 33% in FY22 to 36% in FY24.
"Chronic share percentage for Mankind Pharma has been continuously increasing from 22 to 24 where their share has increased from 33 to 34 and now at 36."
Pending
Mankind Pharma's chronic disease market share increased from 34% in Q2 FY25 to 35% in Q2 FY26.
"Even if I am talking about q2 fy2 versus 25 the percentage has gone up from 34 to 35"
Pending
Mankind Pharma's sales revenue, operating profit, and PBT are at all-time highs.
"sales revenue is basically at an all time high operating profit at an all time high and PBT also at an all time high"
Pending
Mankind Pharma's trailing twelve months (TTM) sales, operating profit, and PBT are also at all-time highs.
"talking about the yearly numbers and even the TTM for that matter that is also at an all time high sales if I am talking about operating profit again at an all time high if I am talking about PBT this is also at an all time high"
Pending
Mankind Pharma has a very low debt-to-equity ratio, with borrowings close to zero.
"borings has not at all increased significantly so that so that debt to equity ratio is also sorted borings is As good as zero to be honest"
Pending
Mankind Pharma's operating cash flows are steadily rising and have reached an all-time high.
"operating cash flows that has also been steadily rising and is at an all time high"
Pending
Mankind Pharma has achieved the number one position in the gynecology segment following the acquisition of Bharat Serums and Vaccines Limited.
"now Mankind Pharma stands at the number one position even in the gynecology segment"
Pending
The acquisition of Bharat Serums and Vaccines Limited is expected to increase Mankind Pharma's revenue and improve its EBITDA and overall margins.
"with this acquisition the revenue also will stand to increase there EBITDA margins will improve and overall margins are also set to improve"
Pending
After the acquisition, Mankind Pharma's total export revenue is projected to be around 13%.
"total export revenue post acquisition for Mankind Pharma may stand around 13 per specifically for exports"
Pending
Mankind Pharma management expects to continue its growth of over 15% in the second half of FY25.
"management had mentioned that we believe that we will continue with our growth of 15 plus"
Pending
Mankind Pharma is also expecting an improvement in its EBITDA margins.
"less so they are improving expecting an improvement in the EBITDA margins as well"
Pending
The pharmaceutical sector in India is expected to be a significant growth area in 2025.
"One sector that is making waves in India in 2025 is the pharmaceutical sector."
Pending
News articles suggest that the pharmaceutical sector is expected to continue its positive trend and bounce back in 2025.
"all these news articles mention that yes pharma ideally should keep on continuing this trend pharma should bounce back in 2025"
Pending